"\"C\u00EDlem projektu je v\u00FDvoj a preklinick\u00E9 testov\u00E1n\u00ED nov\u00E9ho typu \u017Eiv\u00FDch or\u00E1ln\u00EDch vakc\u00EDn pro slizni\u010Dn\u00ED imunizaci proti z\u00E1va\u017En\u00FDm infekc\u00EDm lid\u00ED a hospod\u00E1\u0159sk\u00FDch zv\u00ED\u0159at. K tomu pou\u017Eijeme preklinicky ov\u011B\u0159en\u00FD vektor antigen\u016F, adenyl\u00E1t cyklasov\u00FD toxoid (dACT), schopn\u00FD dopravovat zabudovan\u00E9 antigeny pro prezentaci dendritick\u00FDmi bu\u0148kami a zprost\u0159edkovat indukci specifick\u00E9 protil\u00E1tkov\u00E9 i bun\u011B\u010Dn\u00E9 imunitn\u00ED odpov\u011Bdi. Otestujeme mo\u017Enost praktick\u00E9 aplikace ACT formou \u017Eiv\u00FDch rekombinantn\u00EDch bakteri\u00E1ln\u00EDch vakc\u00EDn produkuj\u00EDc\u00EDch vakcina\u010Dn\u00ED antigeny fuzovan\u00E9 s ACT p\u0159\u00EDmo na sliznici. K tomu pou\u017Eijeme jako nosi\u010D probiotick\u00FD kmen E. coli O83:K24:H3l, kter\u00FD je sou\u010D\u00E1st\u00ED schv\u00E1len\u00E9ho vakcina\u010Dn\u00EDho prepar\u00E1tu \"\"Colinfant Newborn\"\" a vykazuje unik\u00E1tn\u00ED schopnost kolonizovat lidi i selata a p\u016Fsobit preventivn\u011B proti st\u0159evn\u00EDm infekc\u00EDm. O\u010Dek\u00E1v\u00E1me, \u017Ee takto p\u0159ipraven\u00E9 \u017Eiv\u00E9 rekombinantn\u00ED vakc\u00EDny budou indukovat siln\u00E9 a specifick\u00E9 slizni\u010Dn\u00ED imunitn\u00ED odpov\u011Bdi a to umo\u017En\u00ED dal\u0161\u00ED v\u00FDvoj \u00FA\u010Dinn\u00FDch or\u00E1ln\u00EDch vakc\u00EDn.\""@cs . "10"^^ . "0"^^ . . "Vakc\u00EDny pro indukci slizni\u010Dn\u00ED a systemick\u00E9 imunity"@cs . . . "5365"^^ . . . "1"^^ . . "0"^^ . "live vaccine vectors;mucosal vaccine;piglets;probiotic E. coli;pathogen;protective antigen;mucosal immunity"@en . . "Vaccines for induction of mucosal and systemic immunity"@en . . "The goal of this project is to develop and perform preclinical testing of live oral vaccines for mucosal immunization against selected human and veterinary pathogens. Towards this goal we will use a preclinically established antigen vector targeting antigen presenting cells, the adenylate cyclase toxoid (ACT), that can mediate induction of antige-specific humoral and cellular immune responses. We will examine the possibility of delivering ACT directly to mucosal surfaces by the means of a live E. coli strain O83:K24:H3l, which has already been clinically tested and licensed as the COLINFANT Newborn vaccine for prevention of diarrheal and nosocomial infections in infants. Since this strain exhibits a unique capacity to colonize human and porcine intestines, it is expected that it will allow sustained delivery of the ACT-antigen fusions to the mucosal immune system and the induction of strong, specific and protective mucosal immune responses that will allow protective oral vaccination."@en . "6070"^^ . "10"^^ . . . .